One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial

Huang, Hung-Ling; Lee, Meng-Rui; Lee, Chih-Hsin; Cheng, Meng-Hsuan; Lu, Po-Liang; Sheu, Chau-Chyun; Wang, Jann-Yuan; Chong, Inn-Wen; Yang, Jinn-Moon

doi:10.1016/j.cmi.2024.06.024

Clinical Microbiology and Infection

2024

DOI: 10.1016/j.cmi.2024.06.024

|View full text |Cite

One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial

Hung-Ling Huang,

Meng-Rui Lee,

Chih-Hsin Lee

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Re: One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection treatment in non-HIV population by Huang et al.

Xiao

2024

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Re: One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection treatment in non-HIV population by Huang et al.

Xiao

2024

Clinical Microbiology and Infection

View full text Add to dashboard Cite

‘One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial’ – author's response

Huang,

Lee,

Lee

et al. 2024

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Expanding evidence for shortened treatment of latent tuberculosis infection: progress, not perfection

Beeson,

Reves,

Belknap

2024

Clinical Microbiology and Infection

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial

Cited by 3 publications

References 27 publications

Re: One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection treatment in non-HIV population by Huang et al.

Re: One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection treatment in non-HIV population by Huang et al.

‘One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial’ – author's response

Expanding evidence for shortened treatment of latent tuberculosis infection: progress, not perfection

Contact Info

Product

Resources

About